High fees hinder European patents:
This article was originally published in Clinica
Executive Summary
High administration and translation fees are discouraging European companies from filing patents, reveals a survey by the European Patent Office in Munich (Germany). The EPO is keen to reduce the costs of patenting, particularly as small- and medium-sized companies have filed ever fewer patents in recent years. Fees are lower in the US (USPTO), Japan (JPO) and through national patent offices in Europe. The average cost of an EPO patent, including translation and administration fees is DM 45,510 ($32,000) says Nature (May 25th, 1995).
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.